The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | N | Nervous system | |
2 | N02 | Analgesics | |
3 | N02A | Opioids | |
4 | N02AA | Natural opium alkaloids | |
5 | N02AA55 | Oxycodone and naloxone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 75 mg |
Active Ingredient | Description | |
---|---|---|
Oxycodone and Naloxone |
Oxycodone and naloxone have an affinity for kappa, mu and delta opiate receptors in the brain, spinal cord and peripheral organs (e.g. intestine). Oxycodone acts as opioid-receptor agonist at these receptors and binds to the endogenous opioid receptors in the CNS. By contrast, naloxone is a pure antagonist acting on all types of opioid receptors. Naloxone counteracts opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut. |
Title | Information Source | Document Type | |
---|---|---|---|
TARGIN Prolonged-release tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
TARGINACT Prolonged release tablet | Health Products Regulatory Authority (ZA) | MPI, Generic | |
TARGINACT Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.